Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Total Non-Current Liabilities (2018 - 2025)

Ocular Therapeutix (OCUL) has 10 years of Total Non-Current Liabilities data on record, last reported at $152.9 million in Q4 2025.

  • For Q4 2025, Total Non-Current Liabilities rose 18.18% year-over-year to $152.9 million; the TTM value through Dec 2025 reached $152.9 million, up 18.18%, while the annual FY2025 figure was $152.9 million, 18.18% up from the prior year.
  • Total Non-Current Liabilities reached $152.9 million in Q4 2025 per OCUL's latest filing, up from $137.7 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $160.8 million in Q4 2023 and bottomed at $86.3 million in Q1 2021.
  • Average Total Non-Current Liabilities over 5 years is $119.7 million, with a median of $115.6 million recorded in 2022.
  • Peak YoY movement for Total Non-Current Liabilities: surged 53.27% in 2023, then decreased 19.57% in 2024.
  • A 5-year view of Total Non-Current Liabilities shows it stood at $96.7 million in 2021, then rose by 17.71% to $113.8 million in 2022, then skyrocketed by 41.3% to $160.8 million in 2023, then decreased by 19.57% to $129.3 million in 2024, then grew by 18.18% to $152.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Total Non-Current Liabilities were $152.9 million in Q4 2025, $137.7 million in Q3 2025, and $145.3 million in Q2 2025.